Medical/Pharmaceuticals

Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies

CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma, a transformative immunotherapy...

2024-09-13 09:27 1410

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

CHENGDU, China, Sept.12, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the new drug application for Stapokibart (anti-IL-4Rα monoclonal antibody, trade name:Kangyueda (康悦达), for th...

2024-09-13 00:07 1740

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

Highlights * Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67 Cu-SAR-bisPSMA at the highest dose of 12GBq. * The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 doses of67Cu-SAR-bisPSMA. Two of these participa...

2024-09-12 21:03 1774

E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical and New Zealand's NBL Pharmaceuticals Sign Cooperation Agreement to Expand International Markets

FUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, announced today that after the detailed business and market due diligence conducted by the Company and the detailed busin...

2024-09-12 21:00 4190

GenScript Appoints New Board Members to Drive Global Growth

PISCATAWAY, N.J., Sept. 12, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences products and services, announced the appointment of Dr.Ross Allen Grossman as a Non-Executive Director and Dr.Alphonse Galdes as an Independent Non-Executive Director. Th...

2024-09-12 19:34 1187

Bloomage 2024 Mid-Year Report: International Raw Materials Sales Surpass Domestic Chinese Market's for the First Time

PARSIPPANY, N.J., Sept. 11, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, showcased robust growth in its raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue ofRMB 2.811 bil...

2024-09-11 21:00 981

Collagen tripeptides: a new era of collagen drinks

Collagen is highly valued not only for its anti-aging properties but also for its potential benefits in promoting joint health, weight management, and improving overall wellbeing. TAIPEI, Sept. 11, 2024 /PRNewswire/ -- The 2023 global collagen market was valued atUSD 9.76 billion and is projecte...

2024-09-11 17:00 1201

TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation

TAIPEI, Sept. 11, 2024 /PRNewswire/ -- TCI Co. Ltd. ("TCI", 8436.TWO), a global leader in ODM health and cosmetic products for over 40 years, introduces its cutting-edge GLP-1 formula, a natural blend of plant extracts, probiotics, and prebiotics designed to deliver powerful weight management res...

2024-09-11 15:56 1548

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA.  SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...

2024-09-11 14:25 1135

TTLife Oxygen Concentrator: A VARON-Certified Dealer, Your Reliable Partner in First Aid Preparedness

LOS ANGELES, Sept. 10, 2024 /PRNewswire/ -- TTLife Oxygen Concentrator,   is proud to announce its certification as a VARON-certified dealer of oxygen concentrators. This recognition solidifies TTLife's commitment to delivering high-quality, reliable, safe medica...

2024-09-11 10:50 936

GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia

YONGIN, South Korea, Sept. 10, 2024 /PRNewswire/ -- GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bifarma Adiluhung(Bifarma), a premier stem cell therapy company inIndonesia. This strategic pa...

2024-09-11 09:48 1401

Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024

* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi...

2024-09-10 21:00 1448

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRN...

2024-09-10 20:00 1333

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2 st...

2024-09-10 19:00 932

Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024

JINAN, China, Sept. 10, 2024 /PRNewswire/ -- During the World Conference on Lung Cancer (WCLC) held fromSeptember 7-10, 2024, in San Diego, California, updated findings from the Phase II clinical trial (INTELLECT study) were presented. The study assessed the efficacy and safety of Qilu Pharmaceut...

2024-09-10 18:00 975

The 2024 International (Bozhou) TCM Expo Kicked Off

BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...

2024-09-10 17:55 861

Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation

BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...

2024-09-09 21:09 1109

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...

2024-09-09 21:00 1338

Neurophet-NTU Singapore, recognized for outstanding joint research

- Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that Neurophet and NTU (Nanyang Technological Univers...

2024-09-09 21:00 1444

GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug

SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks t...

2024-09-09 21:00 1157
1 ... 10111213141516 ... 214